"They are so so early... (7 person trial) yet they have today a market cap 50% larger than that of RVX! 

Good on them!
Maybe one day we'll be promoted like we have a potential treatment for something..."

Yes, and thanks for that.  Now, to be fair, the SVA folks have suffered with their stock for years too.  So today was a real vindication for a lot of (previously) miserable longs.  I remember 1 poster from the Calgary area: jwallisca from the Coastal Energy board (CEN) and Oilexco Board (OIL).  He's been with SVA for a long time.  Good on him...there's hope.

I was more curious about if there are a lot of other companies doing islet research, and what the implications are (if any) for T2D.  This trial is strictly for patients with T1D.

I like to follow Daniel Drucker on Twitter because he posts a ton of research on diabetes in general, and on SGLT2i, DPP4i and GLP1 RA research in particular (and how it might impact us).  But I haven't seen him comment on this islet transplant technology yet (unless I missed it)